Larimar Therapeutics financials
$3.14−0.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$34.4M | -$31.1M | -$64.0M | -$49.5M | -$27.8M | -$31.2M | -$31.3M | -$18.3M | -$24.6M | -$16.7M | -$14.2M | -$10.3M |
| Net income | -$32.8M | -$29.6M | -$62.5M | -$47.7M | -$26.2M | -$29.3M | -$28.8M | -$15.5M | -$21.6M | -$14.7M | -$13.0M | -$9.1M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.30 | $-0.31 | $-0.73 | $-0.61 | $-0.41 | $-0.46 | $-0.45 | $-0.24 | $-0.34 | $-0.27 | $-0.30 | $-0.21 |
| EBITDA | -$34.3M | -$31.1M | -$63.9M | -$49.4M | -$27.7M | -$31.1M | -$31.2M | -$18.2M | -$24.5M | -$16.7M | -$14.1M | -$10.3M |
| Operating cash flow | -$44.0M | -$44.6M | -$38.5M | -$28.8M | -$19.4M | -$26.5M | -$21.8M | -$24.5M | -$14.0M | -$10.4M | -$9.3M | -$9.2M |
| Free cash flow | -$44.2M | -$44.6M | -$38.5M | -$28.8M | -$19.4M | -$26.6M | -$22.0M | -$24.6M | -$14.3M | -$10.4M | -$9.5M | -$9.2M |
| Diluted shares | 104.4M | 89.8M | 85.5M | 78.3M | 64.0M | 64.0M | 63.9M | 63.8M | 63.8M | 53.6M | 43.9M | 43.9M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $92.7M | $177.9M | $85.4M | $90.1M | $20.6M | $21.1M |
| Short-term investments | $63.6M | $22.5M | $51.4M | $85.3M | $117.9M | $136.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $165.3M | $208.5M | $145.8M | $187.3M | $150.0M | $170.2M |
| Total liabilities | $37.9M | $50.5M | $67.8M | $48.3M | $30.1M | $25.9M |
| Shareholders' equity | $127.4M | $158.0M | $78.1M | $139.0M | $119.9M | $144.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology